Provided by Tiger Trade Technology Pte. Ltd.

Erasca, Inc.

14.32
-0.2800-1.92%
Post-market: 14.580.2600+1.82%17:42 EDT
Volume:5.19M
Turnover:75.11M
Market Cap:4.44B
PE:-32.60
High:15.29
Open:14.65
Low:14.20
Close:14.60
52wk High:16.41
52wk Low:1.01
Shares:310.00M
Float Shares:223.00M
Volume Ratio:0.64
T/O Rate:2.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4393
EPS(LYR):-0.4393
ROE:-33.27%
ROA:-18.28%
PB:13.65
PE(LYR):-32.60

Loading ...

Erasca Is Maintained at Overweight by JP Morgan

Dow Jones
·
Mar 18

Erasca price target raised to $25 from $24 at JPMorgan

TIPRANKS
·
Mar 18

Does Tango Therapeutics (TNGX) Trial Pact and ESOP Shelf Hint at a Pivotal Strategic Turn?

Simply Wall St.
·
Mar 17

Erasca Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 16

Erasca price target raised to $20 from $12 at Guggenheim

TIPRANKS
·
Mar 16

Mizuho Securities Remains a Buy on Erasca (ERAS)

TIPRANKS
·
Mar 15

Erasca Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Mar 14

Stock Track | Erasca Plummets 5.39% Intraday After Bank of America Maintains Sell Rating with $2 Target

Stock Track
·
Mar 14

Stock Track | Erasca Soars 5.12% Intraday on Positive Analyst Actions Including Price Target Hikes

Stock Track
·
Mar 13

Erasca Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 13

Mizuho Raises Price Target on Erasca to $19 From $16, Keeps Outperform Rating

MT Newswires Live
·
Mar 13

Erasca, Inc. : H.c. Wainwright Raises Target Price to $20 From $15

THOMSON REUTERS
·
Mar 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 13

U.S. RESEARCH ROUNDUP-Adobe, KLA, Ulta Beauty

Reuters
·
Mar 13

Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

GlobeNewswire
·
Mar 13

Erasca: Pan-RAS Data Momentum and Strategic Partnerships Underpin Upsized Revenue Outlook and Buy Rating

TIPRANKS
·
Mar 11

Erasca price target raised to $20 from $10 at Stifel

TIPRANKS
·
Mar 11

Erasca Exercises Option to Extend Cancer Drug Candidate License to Gain Global Rights

MT Newswires Live
·
Mar 10

Erasca Inc - Initial Phase 1 Monotherapy Data for Eras-0015 Expected in H1 2026

THOMSON REUTERS
·
Mar 10

Erasca Inc - Exercises Option to Secure Worldwide Rights for Eras-0015

THOMSON REUTERS
·
Mar 10